Loading
A phase 1/2 trial of Pembrolizumab in melanoma and hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) is a phase 1/2 interventional study registered as NCT02332668 by Merck Sharp & Dohme LLC, with 370 participants planned, started 2015-03-19 and due to reach its primary completion in 2028-02-02. Interventions recorded: Pembrolizumab. Conditions listed: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced melanoma (unresectable stage III and stage IV), Merck & Co. (MSD), Melanoma, Pembrolizumab.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Merck & Co. (MSD), Melanoma, Pembrolizumab.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/